|Bid||228.50 x 0|
|Ask||230.00 x 0|
|Day's range||226.00 - 231.27|
|52-week range||1.93 - 306.50|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||4.09|
|Earnings date||4 Jul 2018 - 9 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||320.00|
Syncona Limited Quarterly Update 9 August 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today issues its quarterly update covering ...
Syncona Limited Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons 2 August 2018 1. Details of PDMR / person closely associated with ...
Pursuant to DTR 5.6.1 Syncona Limited (the “Company”) announces that as at 31 July 2018 the total number of ordinary shares in issue now stands at 661,201,473 and the total number of voting rights in the Company is 661,201,473 ordinary shares. The Company does not hold any ordinary shares in treasury.
Syncona Limited (the "Company") today announces that a total of 1,249,383 new ordinary shares will be issued in satisfaction of the payment of the Company’s 2018 dividend to those qualifying shareholders who did not elect to receive the dividend in cash. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 30 July 2018.
Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet May 2018 Attached is a link to the May 2018 Monthly Fact Sheet for Syncona ...
Syncona Limited (“Syncona”), a leading healthcare company focused on investing in and building global leaders in life science, today announces that it has published its Annual Report and Accounts for the year ended 31 March 2018 (“2018 Annual Report”). In addition, Syncona has published its Notice of Annual General Meeting 2018 and a circular relating to the 2018 Dividend.
Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics plc (“Autolus”) has today announced the pricing of its initial public offering (“IPO”) in the United States of 8,823,530 American Depositary Shares (“ADSs”), at an initial public offering price of $17.00 per ADS for total gross proceeds of approximately $150.0 million (£113.2 million1). All ADSs sold in the IPO were offered by Autolus.